Loading...

CATX PERSPECTIVE THERAPEUTICS INC Product Launches 8-K Filing

PRSP

CTX

PERSPECTIVE THERAPEUTICS INC

(CATX)

2025 8-K

Show Summary

Show Summary

Product Expansion

Financial Statements

Clinical Trials

Clinical Trial Update

Financial Results

Clinical Trial Update

Corporate Update

Corporate Presentation

Financial Update

Management Change

Corporate Update

Corporate Presentation

Financial Results

New Partnership

Management Change

Management Change

Equity Offering

Corporate Presentation

Financial Results Update

Financial Results

Reverse Stock Split

Annual Meeting Approval

Underwriting Agreement

Financial Results Announcement

Completion of Asset Sale

Changes in Accounting Firm

Amendment to Asset Purchase...

Financial Results Announcement

Annual Meeting of Stockholders

Collaboration Agreement and...

Investment Agreement

Presentation Update

Public Offering and Private...

Financial Results

Amendment to Initial Form 8-K

Announcement of Clinical St...

Investment Agreement and As...

Agreement with Mayo Clinic

Conference Participation

Asset Purchase Agreement

Supply Contract

Announcement of Studies and...

Agreement for Equity Program

Annual Meeting Approval

Earnings Report

Investor Meetings

Employment Agreements

Management Changes

Departure of Chief Research...

Closure of Banks

Financial Results Announcement

Termination of Employment A...

Merger Completion

Annual Meeting Results

Annual Meeting Adjournment

External Links:

On March 17, 2025, Perspective Therapeutics, Inc. announced that the first patient was dosed in a new cohort of its Phase 1/2a trial for [212Pb]VMT01, a therapy for melanoma, in combination with nivolumab.

AI Assistant

PERSPECTIVE THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.